Opioid-Free Anesthesia Versus Opioid Based Anesthesia For Adolescent Idiopathic Scoliosis
Opioid-Free Anesthesia Versus Opioid Based Anesthesia For Adolescent Idiopathic Scoliosis A Prospective Randomized Double-Blind Controlled Trial
Nashwa Ahmed
30 participants
Jan 30, 2026
INTERVENTIONAL
Summary
Opioid-free anesthesia (OFA) is a multimodal analgesic approach designed to eliminate the intraoperative use of systemic, neuraxial, or intracavitary opioids. This technique employs a combination of antinociceptive agents targeting various pathways within the central and peripheral nervous systems to achieve effective analgesia. Dexmedetomidine (DEX), a highly selective α2-adrenoreceptor agonist, is a centrally acting non-opioid agent increasingly utilized in clinical practice for its antinociceptive and anxiolytic properties. Only a few prospective randomized controlled trials have specifically examined the postoperative analgesic efficacy of intraoperative dexmedetomidine infusion in patients undergoing spinal surgery, with limited data focusing on this as a primary endpoint. Importantly, no clinical studies have investigated its analgesic impact in patients undergoing spinal surgery under general anesthesia.
Eligibility
Inclusion Criteria1
- \-
Exclusion Criteria12
- Non-idiopathic scoliosis
- Contraindications to commonly used perioperative medications
- ASA Physical Status ≥ III
- Presence of neuromuscular disorders or severe cardiac dysfunction
- Requirement for postoperative mechanical ventilation
- Regular use of analgesics or opioids
- History of allergy to opioids or dexmedetomidine
- Diagnosed mental disorders
- Severe hepatic or renal dysfunction
- Coagulopathy or significant pulmonary disease
- Preoperative or postoperative neurological deficits
- Occurrence of serious arrhythmia, hypotension, or bradycardia necessitating discontinuation of dexmedetomidine infusion
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
patients will Receive dexmedetomidine with a loading dose of 1 μg/kg followed by a maintenance infusion of 0.5 μg/kg/h.
patients will Receive fentanyl with a loading dose of 1 μg/kg followed by a maintenance infusion of 0.5 μg/kg/h.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07389096